Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc. (BCRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: BioCryst is a global biotechnology company focused on developing oral small-molecule and protein therapeutics for complement-mediated and other rare diseases. Its primary commercial product is ORLADEYO® (berotralstat) for hereditary angioedema (HAE). The company also holds rights to RAPIVAB® (peramivir) for influenza and maintains a pipeline of complement inhibitors and other rare disease candidates.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $109,332 | $82,491 | $202,093 | $151,269 |
| Net Loss | $(12,674) | $(75,326) | $(48,053) | $(128,659) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.40) | $(0.23) | $(0.68) |
| Operating Cash Flow | — | — | $(55,052) | $(66,326) |
| Cash & Cash Equivalents | $78,410 | — | $78,410 | — |
| Total Investments | $257,934 | — | $257,934 | — |
| Total Debt (Secured Term Loan) | $313,822 | — | $313,822 | — |
| Royalty Financing Obligations | $523,633 | — | $523,633 | — |
Note: Q2 2023 Net Loss included a one-time $29.0 million loss on extinguishment of debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32.5% in Q2 2024 compared to Q2 2023, driven primarily by a $27.3 million increase in ORLADEYO net revenue. YTD revenue increased 33.6%.
- Improved Profitability: The company reported an operating income of $8.8 million in Q2 2024, a significant improvement from an operating loss of $20.7 million in Q2 2023. This was driven by revenue growth and reduced R&D expenses.
- R&D Expense Reduction: R&D expenses decreased 26.6% in Q2 2024 ($37.6M) compared to Q2 2023 ($51.2M), primarily due to decreased spending on the Factor D program (BCX10013) and the discontinuation of the BCX9930 program.
- SG&A Increase: Selling, general, and administrative expenses increased 20.0% in Q2 2024 ($61.2M) compared to Q2 2023 ($51.0M), attributed to increased commercial expenses to support growing revenue and expanded international operations.
- Debt Structure: The company repaid its Athyrium Credit Agreement in April 2023 and is now servicing the Pharmakon Loan Agreement. Interest expense decreased in Q2 2024 compared to Q2 2023, partially due to the absence of the Athyrium debt extinguishment loss.
Guidance, Outlook, and Risks
- Product Discontinuation: On August 5, 2024, the company announced plans to discontinue development of BCX10013 (Factor D inhibitor) after clinical evaluation showed activity levels lower than other market therapies.
- ORLADEYO Expansion: The company remains on track to submit a regulatory filing in 2025 to expand the ORLADEYO label to children as young as two years of age. Recent approvals were received in Brazil, Mexico, and Peru.
- Liquidity Outlook: Management believes current financial resources (cash, cash equivalents, and investments totaling approx. $336 million) are sufficient to fund operations for at least the next 12 months. However, the company expects total 2024 expenses to exceed total 2024 revenues.
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting due to insufficient staffing in the accounting function, which restricts the ability to consistently execute review procedures. Remediation efforts are underway.
- Debt Covenants: The Pharmakon Loan Agreement contains restrictive covenants limiting additional indebtedness, asset dispositions, and dividends. A material adverse change could trigger an event of default.
Investor Verification Checklist
- ORLADEYO Sales Trajectory: Verify the sustainability of the 32.5% Q2 revenue growth and the impact of the new pediatric formulation filing on future peak revenue projections.
- BCX10013 Discontinuation Impact: Assess the financial and strategic implications of discontinuing the Factor D program and the potential for royalty obligations on this asset to be re-evaluated.
- Internal Control Remediation: Monitor the progress of hiring and process updates to remediate the material weakness in internal controls over financial reporting.
- Debt Service Capacity: Review the company's ability to service the $313.8 million Pharmakon term loan and $523.6 million royalty financing obligations as ORLADEYO sales fluctuate.
- Workforce Reduction Costs: Confirm that the $1.3 million in one-time termination benefits recognized in Q1 2024 represents the full extent of costs related to the January 2024 workforce reduction.